NCT05267743View on ClinicalTrials.gov

Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

May 25, 2022

Study Completion Date

May 25, 2022

Conditions
Erosive Reflux Disease
Interventions
DRUG

Tegoprazan 50mg QD

Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.

DRUG

Lansoprazole 30mg QD

Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.

Trial Locations (1)

54538

Wonkwang University Hospital, Iksan

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY

NCT05267743 - Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease | Biotech Hunter | Biotech Hunter